JP2017534262A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534262A5
JP2017534262A5 JP2017515139A JP2017515139A JP2017534262A5 JP 2017534262 A5 JP2017534262 A5 JP 2017534262A5 JP 2017515139 A JP2017515139 A JP 2017515139A JP 2017515139 A JP2017515139 A JP 2017515139A JP 2017534262 A5 JP2017534262 A5 JP 2017534262A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
nucleotide sequence
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017515139A
Other languages
English (en)
Other versions
JP2017534262A (ja
JP6657195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/051089 external-priority patent/WO2016044811A1/en
Publication of JP2017534262A publication Critical patent/JP2017534262A/ja
Publication of JP2017534262A5 publication Critical patent/JP2017534262A5/ja
Priority to JP2020017583A priority Critical patent/JP6986190B2/ja
Application granted granted Critical
Publication of JP6657195B2 publication Critical patent/JP6657195B2/ja
Priority to JP2021169396A priority patent/JP7171871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (16)

  1. 配列番号１０のアミノ酸を含むキメラ抗原レセプター分子をコードする核酸分子。
  2. 請求項１に記載の前記核酸分子を含む発現ベクター。
  3. 当該発現ベクターはレンチウイルスベクターである、請求項２に記載の発現ベクター。
  4. 前記キメラ抗原レセプターをコードする前記ヌクレオチド配列に先行するＧＭＳＣＦＲａシグナル配列をコードするヌクレオチド配列をさらに含む、請求項１に記載の核酸分子。
  5. 前記ＧＭＳＣＦＲａシグナル配列が、配列番号２のアミノ酸配列を含む、請求項４に記載の核酸分子。
  6. 前記キメラ抗原レセプターをコードする前記ヌクレオチド配列に続くＴ２Ａリボソームスキップ配列をコードするヌクレオチド配列をさらに含む、請求項４に記載の核酸分子。
  7. Ｔ２Ａリボソームスキップ配列が、配列番号８のアミノ酸配列を含む、請求項６に記載の核酸分子。
  8. 請求項４に記載の前記核酸分子を含む発現ベクター。
  9. 前記発現ベクターがレンチウイルスベクターである、請求項８に記載の発現ベクター。
  10. 前記キメラ抗原レセプターをコードする前記ヌクレオチド配列に続くＴ２Ａリボソームスキップ配列をコードするヌクレオチド配列をさらに含む、請求項１に記載の核酸分子。
  11. Ｔ２Ａリボソームスキップ配列が、配列番号８のアミノ酸配列を含む、請求項１０に記載の核酸分子。
  12. 前記Ｔ２Ａリボソームスキップ配列をコードする前記ヌクレオチド配列に続く短縮型ＣＤ１９をコードするヌクレオチド配列をさらに含む、請求項１０に記載の核酸分子。
  13. 前記短縮型ＣＤ１９が、配列番号９のアミノ酸配列を含む、請求項１２に記載の核酸分子。
  14. 前記短縮型ＣＤ１９が配列番号９のアミノ酸配列からなる、請求項１２に記載の核酸分子。
  15. 短縮型ＣＤ１９をコードするヌクレオチド配列をさらに含む、請求項１に記載の核酸分子。
  16. 前記短縮型ＣＤ１９が、配列番号９のアミノ酸配列を含む、請求項１５に記載の核酸分子。
JP2017515139A 2014-09-19 2015-09-18 Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 Active JP6657195B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020017583A JP6986190B2 (ja) 2014-09-19 2020-02-05 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
JP2021169396A JP7171871B2 (ja) 2014-09-19 2021-10-15 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053068P 2014-09-19 2014-09-19
US62/053,068 2014-09-19
PCT/US2015/051089 WO2016044811A1 (en) 2014-09-19 2015-09-18 COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020017583A Division JP6986190B2 (ja) 2014-09-19 2020-02-05 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞

Publications (3)

Publication Number Publication Date
JP2017534262A JP2017534262A (ja) 2017-11-24
JP2017534262A5 true JP2017534262A5 (ja) 2018-10-25
JP6657195B2 JP6657195B2 (ja) 2020-03-04

Family

ID=55533940

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2017515139A Active JP6657195B2 (ja) 2014-09-19 2015-09-18 Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
JP2017515138A Active JP6711819B2 (ja) 2014-09-19 2015-09-21 養子ｔ細胞療法のためのセントラルメモリーｔ細胞
JP2020017583A Active JP6986190B2 (ja) 2014-09-19 2020-02-05 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
JP2020093109A Active JP7216045B2 (ja) 2014-09-19 2020-05-28 養子ｔ細胞療法のためのセントラルメモリーｔ細胞
JP2021169396A Active JP7171871B2 (ja) 2014-09-19 2021-10-15 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞
JP2022176776A Pending JP2023014100A (ja) 2014-09-19 2022-11-02 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
JP2023006410A Ceased JP2023052506A (ja) 2014-09-19 2023-01-19 養子ｔ細胞療法のためのセントラルメモリーｔ細胞

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2017515138A Active JP6711819B2 (ja) 2014-09-19 2015-09-21 養子ｔ細胞療法のためのセントラルメモリーｔ細胞
JP2020017583A Active JP6986190B2 (ja) 2014-09-19 2020-02-05 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
JP2020093109A Active JP7216045B2 (ja) 2014-09-19 2020-05-28 養子ｔ細胞療法のためのセントラルメモリーｔ細胞
JP2021169396A Active JP7171871B2 (ja) 2014-09-19 2021-10-15 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞
JP2022176776A Pending JP2023014100A (ja) 2014-09-19 2022-11-02 ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
JP2023006410A Ceased JP2023052506A (ja) 2014-09-19 2023-01-19 養子ｔ細胞療法のためのセントラルメモリーｔ細胞

Country Status (15)

Country Link
US (3) US9914909B2 (ja)
EP (4) EP3587446A1 (ja)
JP (7) JP6657195B2 (ja)
KR (3) KR102683584B1 (ja)
CN (4) CN107002084B (ja)
AU (4) AU2015317351B2 (ja)
BR (3) BR122024000360A2 (ja)
CA (2) CA2961654A1 (ja)
DK (1) DK3200591T3 (ja)
ES (2) ES2738705T3 (ja)
HK (1) HK1247046A1 (ja)
IL (6) IL292650B2 (ja)
MX (4) MX2017003596A (ja)
RU (2) RU2749922C2 (ja)
WO (2) WO2016044811A1 (ja)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
AU2015317351B2 (en) 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
AU2016297605A1 (en) 2015-07-21 2018-02-15 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
RU2724738C2 (ru) * 2015-08-05 2020-06-25 СеллабМЕД ИНК. Химерный антигенный рецептор и т-клетки, в которых экспрессируется химерный антигенный рецептор
IL262061B2 (en) * 2016-04-01 2023-03-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
SG11201808403SA (en) * 2016-04-01 2018-10-30 Kite Pharma Inc Bcma binding molecules and methods of use thereof
SI3436079T1 (sl) 2016-04-01 2022-01-31 Kite Pharma, Inc. Himerni antigen in T celični receptorji ter način uporabe
UA128781C2 (uk) 2016-04-01 2024-10-23 Кайт Фарма, Інк. Т-клітина, спосіб її отримання та застосування
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
KR20230042703A (ko) * 2016-06-07 2023-03-29 맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
AU2017279548B2 (en) * 2016-06-08 2024-08-08 Precigen, Inc. CD33 specific chimeric antigen receptors
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7002769B2 (ja) * 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
JP7217970B2 (ja) 2016-10-07 2023-02-06 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018102761A1 (en) 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
US20200078401A1 (en) * 2016-12-07 2020-03-12 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
US12083148B2 (en) * 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
US20210122831A1 (en) * 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
US20200215132A1 (en) * 2017-08-11 2020-07-09 City Of Hope Oncolytic virus expressing a car t cell target and uses thereof
CA3080109A1 (en) * 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN111936518A (zh) * 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
CN111971053A (zh) * 2018-02-12 2020-11-20 综合医院公司 靶向肿瘤微环境的嵌合抗原受体
MX2020009464A (es) * 2018-03-14 2021-01-15 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Inmunoterapia de células t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13.
EP3765041A4 (en) * 2018-03-14 2021-12-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) IL-13 ALPHA 2 RECEPTOR CHEMICAL ANTIGENIC RECEPTOR (IL13RA2) FOR TUMOR-SPECIFIC T-LYMPHOCYTE IMMUNOTHERAPY
KR20210013691A (ko) * 2018-05-21 2021-02-05 바이오셉터 (유케이) 리미티드 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도
US20210214410A1 (en) * 2018-06-01 2021-07-15 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
AU2019295855A1 (en) 2018-06-29 2021-01-28 City Of Hope CD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
JP7495137B2 (ja) * 2018-08-10 2024-06-04 ユーティレックス カンパニー リミテッド 癌抗原特異的細胞傷害性ｔ細胞
WO2020191336A1 (en) 2019-03-21 2020-09-24 Yamaguchi, Yukiko Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
WO2020205751A1 (en) 2019-03-29 2020-10-08 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
WO2021183755A1 (en) * 2020-03-11 2021-09-16 City Of Hope Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
CA3175123A1 (en) * 2020-03-12 2021-09-16 City Of Hope Targeted chimeric antigen receptor modified t cells for treatment of il13r.alpha.2 positive malignancies
WO2021242719A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN116963759A (zh) * 2020-09-10 2023-10-27 野马生物股份有限公司 包含靶向癌症的car-t细胞的组合疗法及使用其治疗癌症的方法
US20230364138A1 (en) 2020-11-23 2023-11-16 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN118146395A (zh) * 2021-02-08 2024-06-07 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
US20240158521A1 (en) * 2021-03-18 2024-05-16 The Wistar Institute Of Anatomy And Biology DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS
JP2024514308A (ja) 2021-03-30 2024-04-01 シティ・オブ・ホープ ＣＡＲ Ｔ細胞療法及びＩＦＮγ
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
EP4176895A1 (en) * 2021-11-08 2023-05-10 AvenCell Europe GmbH Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
WO2023130462A1 (zh) * 2022-01-10 2023-07-13 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
NZ337002A (en) * 1995-02-24 2005-07-29 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
PT1100529E (pt) 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US11278594B2 (en) * 2001-04-30 2022-03-22 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
ATE373904T1 (de) 2003-07-24 2007-10-15 Matsushita Electric Ind Co Ltd Verfahren, kodierer und kommunikationsvorrichtung zur kodierung von parallel verketteten daten
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7754441B2 (en) * 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DE102004043271A1 (de) * 2004-09-07 2006-03-09 Linde Ag Verfahren zur Synthese von Zirkoniumcarboxylaten
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
CA2634072A1 (en) * 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
DE602006017435D1 (de) * 2005-12-21 2010-11-18 Sentoclone Ab Verfahren zur expansion tumorreaktiver t-lymphozyten zur immuntherapie von patienten mit krebs
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
CN104004088B (zh) * 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
US8822647B2 (en) * 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
AU2010334974A1 (en) * 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
GB2481983A (en) * 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
EP2606124A1 (en) * 2010-08-18 2013-06-26 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of identifying central memory t cells and obtaining antigen-specific t cell populations
DK3214091T3 (en) * 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
RU2688185C2 (ru) * 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
EP2532740A1 (en) * 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US10780118B2 (en) * 2012-08-20 2020-09-22 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
WO2015105522A1 (en) * 2014-01-13 2015-07-16 Forman Stephen J Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
AU2015317351B2 (en) † 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2

Similar Documents

Publication Publication Date Title
JP2017534262A5 (ja)
JP2015096070A5 (ja)
JP2014012688A5 (ja)
JP2017048194A5 (ja)
CA3062698A1 (en) Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
JP2011155981A5 (ja)
WO2018004308A3 (ko) 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법
JP2016185981A5 (ja)
JP2010088434A5 (ja)
JP2016104015A5 (ja)
MX2017016105A (es) Polinucleotidos y polipeptidos de adenovirus.
JP2010227108A5 (ja)
CL2013001124A1 (es) Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo.
JP2014518898A5 (ja)
JP2018531624A5 (ja)
JP2015038108A5 (ja)
EA201990884A1 (ru) АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
SG10201909180SA (en) Humanized anti-c1s antibodies and methods of use thereof
JP2014028813A5 (ja)
JP2013539454A5 (ja)
WO2015181119A3 (en) Lipase variants and polynucleotides encoding same
JP2017525355A5 (ja)
EP3929285A3 (en) Methods of reducing odor
WO2019034703A3 (en) MODIFICATION OF LYMPHOCYTES T
WO2015109951A8 (zh) 一种人源抗虫基因及其编码的抗Cry1Ab毒素独特型单链抗体与应用